Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

349 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Two-year real-life efficacy, tolerability and safety of dimethyl fumarate in an Italian multicentre study.
Mallucci G, Annovazzi P, Miante S, Torri-Clerici V, Matta M, La Gioia S, Cavarretta R, Mantero V, Costantini G, D'Ambrosio V, Zaffaroni M, Ghezzi A, Perini P, Rossi S, Bertolotto A, Rottoli MR, Rovaris M, Balgera R, Cavalla P, Montomoli C, Bergamaschi R. Mallucci G, et al. Among authors: zaffaroni m. J Neurol. 2018 Aug;265(8):1850-1859. doi: 10.1007/s00415-018-8916-6. Epub 2018 Jun 14. J Neurol. 2018. PMID: 29948245
Safety and efficacy of natalizumab in children with multiple sclerosis.
Ghezzi A, Pozzilli C, Grimaldi LM, Brescia Morra V, Bortolon F, Capra R, Filippi M, Moiola L, Rocca MA, Rottoli M, Sarchielli P, Zaffaroni M, Comi G. Ghezzi A, et al. Among authors: zaffaroni m. Neurology. 2010 Sep 7;75(10):912-7. doi: 10.1212/WNL.0b013e3181f11daf. Neurology. 2010. PMID: 20820002 Free article. Clinical Trial.
Changes in magnetic resonance imaging disease measures over 3 years in mildly disabled patients with relapsing-remitting multiple sclerosis receiving interferon β-1a in the COGnitive Impairment in MUltiple Sclerosis (COGIMUS) study.
Bastianello S, Giugni E, Amato MP, Tola MR, Trojano M, Galletti S, Luccichenti G, Quarantelli M, Picconi O, Patti F; COGIMUS study group. Bastianello S, et al. BMC Neurol. 2011 Oct 14;11:125. doi: 10.1186/1471-2377-11-125. BMC Neurol. 2011. PMID: 21999142 Free PMC article. Clinical Trial.
Patient adherence to and tolerability of self-administered interferon β-1a using an electronic autoinjection device: a multicentre, open-label, phase IV study.
Lugaresi A, Florio C, Brescia-Morra V, Cottone S, Bellantonio P, Clerico M, Centonze D, Uccelli A, di Ioia M, De Luca G, Marcellusi A, Paolillo A; BRIDGE study group. Lugaresi A, et al. BMC Neurol. 2012 Mar 5;12:7. doi: 10.1186/1471-2377-12-7. BMC Neurol. 2012. PMID: 22390218 Free PMC article. Clinical Trial.
Risk of multiple sclerosis relapses when switching from fingolimod to cell-depleting agents: the role of washout duration.
Ferraro D, Iaffaldano P, Guerra T, Inglese M, Capobianco M, Brescia Morra V, Zaffaroni M, Mirabella M, Lus G, Patti F, Cavalla P, Cellerino M, Malucchi S, Pisano E, Vitetta F, Paolicelli D, Sola P, Trojano M; Italian MS Register. Ferraro D, et al. Among authors: zaffaroni m. J Neurol. 2022 Mar;269(3):1463-1469. doi: 10.1007/s00415-021-10708-1. Epub 2021 Jul 22. J Neurol. 2022. PMID: 34292396
A post-marketing study on interferon beta 1b and 1a treatment in relapsing-remitting multiple sclerosis: different response in drop-outs and treated patients.
Milanese C, La Mantia L, Palumbo R, Martinelli V, Murialdo A, Zaffaroni M, Caputo D, Capra R, Bergamaschi R; North Italy Multiple Sclerosis Group. Milanese C, et al. Among authors: zaffaroni m. J Neurol Neurosurg Psychiatry. 2003 Dec;74(12):1689-92. doi: 10.1136/jnnp.74.12.1689. J Neurol Neurosurg Psychiatry. 2003. PMID: 14638892 Free PMC article.
349 results